Amgen Inc. (AMGN)
-NasdaqGS 101.50 
2.42(2.44%) 4:00PM EDT|After Hours
:
101.50 0.00 (0.00%) 5:54PM EDT
| Prev Close: | 99.08 |
|---|
| Open: | 99.28 |
|---|
| Bid: | 101.50 x 400 |
|---|
| Ask: | 101.99 x 100 |
|---|
| 1y Target Est: | 113.41 |
|---|
| Beta: | 0.43 |
|---|
| Next Earnings Date: | 22-Jul-13 |
|---|
| Day's Range: | 99.07 - 102.29 |
|---|
| 52wk Range: | 70.88 - 114.95 |
|---|
| Volume: | 3,328,943 |
|---|
| Avg Vol (3m): | 3,869,280 |
|---|
| Market Cap: | 76.12B |
|---|
| P/E (ttm): | 17.18 |
|---|
| EPS (ttm): | 5.91 |
|---|
| Div & Yield: | 1.88 (1.90%) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- On The Fly: After Hours Moversat theflyonthewall.com(Tue 7:07PM EDT)
- Final Glance: Biotechnology companiesAP(Tue 6:01PM EDT)
- Midday Glance: Biotechnology companiesAP(Tue 1:17PM EDT)
- Three Attractive, Future Dividend Achieversat Motley Fool(Tue 12:55PM EDT)
- Top Treatments for High Cholesterolat Motley Fool(Tue 12:26PM EDT)
- Early Glance: Biotechnology companiesAP(Tue 10:21AM EDT)
- InPlay: Amgen displays early relative strength but stalls shy of its June high and 50 ema at 101.25/101.31 -- session high 100.99Briefing.com(Tue 9:35AM EDT)
- Amgen Xgeva Label ExpandedZacks(Mon, Jun 17)
- American Generics Can't Touch This $8 Billion Drug (Yet)at Motley Fool(Mon, Jun 17)
- 5 Stocks Raising The Drugs Industry Higherat TheStreet(Mon, Jun 17)
- Huge Upside on Pipeline Strengthat Motley Fool(Mon, Jun 17)
- Today's Market: Biotech And Cable M&A The Big Storiesat Seeking Alpha(Mon, Jun 17)
- Amgen share buybacks, drugs may fuel more stock gains - Barron'sReuters(Sun, Jun 16)
- Taking Care Of Yourself And Your Property Through These Stocksat Seeking Alpha(Sun, Jun 16)
- 3 Winners and 2 Losers From Rigel's Failureat Motley Fool(Sat, Jun 15)
Key Statistics
| Forward P/E (1 yr): | 12.24 |
|---|
| P/S (ttm): | 4.26 |
|---|
| Ex-Dividend Date: | 14-May-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 7.28 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 1.74 |
|---|
| Mean Recommendation*: | 2.4 |
|---|
| PEG Ratio (5 yr expected): | 1.42 |
|---|
Business Summary
Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the Uni...
View More